Ignite Creation Date:
2024-05-05 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00234871
Status:
COMPLETED
Last Update Posted:
2008-07-15
First Post:
2005-09-13
Brief Title:
Tarka vs Lotrel in Hypertensive Diabetic Subjects With Renal Disease TANDEM
Sponsor:
Abbott
Organization:
Abbott
Study Overview
Official Title:
A Phase IV Randomized Open-Label Active Controlled Study to Compare the Effects of Tarka and Lotrel on Albuminuria in Hypertensive Type 2 Diabetic Subjects With Diabetic Nephropathy
Status:
COMPLETED
Status Verified Date:
2008-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TANDEM
Brief Summary:
The primary objective of this study is to determine if trandolaprilverapamil Tarka is superior to amlodipinebenazepril Lotrel in reduction of albuminuria in hypertensive subjects with Type 2 diabetes mellitus DM and diabetic nephropathy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None